Home · Health · Sep 29 archive
Primary Care Providers Navigate GLP-1 Medication Switches
Developing
In Short: Primary care providers are increasingly handling medication switches involving GLP-1 receptor agonists and dual incretin agents as these treatments become more common for obesity and type 2 diabetes, according to new guidance published in Clinical Diabetes.
Primary care providers are increasingly handling medication switches involving GLP-1 receptor agonists and dual incretin agents as these treatments become more common for obesity and type 2 diabetes, according to new guidance published in Clinical Diabetes.
Guidance from the American Diabetes Association’s Standards of Care in Overweight and Obesity emphasizes a person-centered approach, taking into account factors such as access, tolerability, side effects, and patient preferences.
Susan Spratt, MD, a professor at Duke University School of Medicine, advises that if a patient has not been on a GLP-1 agonist for more than 2-3 weeks, the dose should be retitrated to avoid gastrointestinal intolerance.
Primary care providers should also prepare to reduce or temporarily hold insulin or sulfonylurea doses as the new GLP-1 agent begins to take effect.
This step-by-step planning is crucial for ensuring that patients transition smoothly between different GLP-1 receptor agonists and dual incretin agents, optimizing their treatment outcomes.
What's still developing
- Nothing material beyond the confirmed record.